CN102416217B - 药物治疗球囊扩张导管 - Google Patents
药物治疗球囊扩张导管 Download PDFInfo
- Publication number
- CN102416217B CN102416217B CN201110261928.1A CN201110261928A CN102416217B CN 102416217 B CN102416217 B CN 102416217B CN 201110261928 A CN201110261928 A CN 201110261928A CN 102416217 B CN102416217 B CN 102416217B
- Authority
- CN
- China
- Prior art keywords
- sacculus
- catheter
- chamber
- medicine
- expansion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 156
- 229940079593 drug Drugs 0.000 title claims abstract description 58
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 50
- 239000008280 blood Substances 0.000 claims abstract description 29
- 210000004369 blood Anatomy 0.000 claims abstract description 29
- 230000000916 dilatatory effect Effects 0.000 claims description 40
- 238000007789 sealing Methods 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000010409 thin film Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000001575 pathological effect Effects 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000008602 contraction Effects 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 description 13
- 208000037803 restenosis Diseases 0.000 description 11
- 230000002792 vascular Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 4
- 238000002399 angioplasty Methods 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 229950000844 mizoribine Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 231100000216 vascular lesion Toxicity 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 229960000556 fingolimod Drugs 0.000 description 3
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- IDINUJSAMVOPCM-UHFFFAOYSA-N 15-Deoxyspergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 108010056764 Eptifibatide Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- ZZIKIHCNFWXKDY-UHFFFAOYSA-N Myriocin Natural products CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O ZZIKIHCNFWXKDY-UHFFFAOYSA-N 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- OGBPBDMDXNFPCS-UHFFFAOYSA-N Prodigiosin-25C Natural products C1=CC(CCCCCCCCCCC)=NC1=CC1=C(OC)C=C(C=2NC=CC=2)N1 OGBPBDMDXNFPCS-UHFFFAOYSA-N 0.000 description 2
- GDVNLLJNADMLLR-BBRMVZONSA-N Spergualin Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)C[C@@H](O)CCCCN=C(N)N GDVNLLJNADMLLR-BBRMVZONSA-N 0.000 description 2
- JBVZQDJNGFOSNX-UHFFFAOYSA-N Spergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CC(O)CCCCNC(=CN)N JBVZQDJNGFOSNX-UHFFFAOYSA-N 0.000 description 2
- 241001655322 Streptomycetales Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 2
- 229950001858 batimastat Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- PZOHOALJQOFNTB-UHFFFAOYSA-M brequinar sodium Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- QCUFYOBGGZSFHY-UHFFFAOYSA-N depsidomycin Chemical compound O=C1C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(NC=O)C(C)CC)C(C)OC(=O)C2CCCNN2C(=O)C(CC(C)C)NC(=O)C2CCCNN21 QCUFYOBGGZSFHY-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960004468 eptifibatide Drugs 0.000 description 2
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 2
- 125000001033 ether group Chemical group 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- ZZIKIHCNFWXKDY-GNTQXERDSA-N myriocin Chemical compound CCCCCCC(=O)CCCCCC\C=C\C[C@@H](O)[C@H](O)[C@@](N)(CO)C(O)=O ZZIKIHCNFWXKDY-GNTQXERDSA-N 0.000 description 2
- BLUYEPLOXLPVCJ-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxyethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC[C@H](O)NC(=O)CCCCCCNC(N)=N BLUYEPLOXLPVCJ-INIZCTEOSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229960002340 pentostatin Drugs 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960003425 tirofiban Drugs 0.000 description 2
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 2
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 2
- 229960005342 tranilast Drugs 0.000 description 2
- 210000004026 tunica intima Anatomy 0.000 description 2
- HIYSWASSDOXZLC-HKOYGPOVSA-N undecylprodigiosin Chemical compound N1C(CCCCCCCCCCC)=CC=C1\C=C\1C(OC)=CC(C=2NC=CC=2)=N/1 HIYSWASSDOXZLC-HKOYGPOVSA-N 0.000 description 2
- 150000000307 17β-estradiols Chemical class 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- YHFUPQNXMNMQAK-UHFFFAOYSA-N Elsibucol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(SC(C)(C)SC=2C=C(C(OCCCC(O)=O)=C(C=2)C(C)(C)C)C(C)(C)C)=C1 YHFUPQNXMNMQAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- -1 abciximab Chemical compound 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 108010017278 depsidomycin Proteins 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 229940083410 myfortic Drugs 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical group C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- NESLWCLHZZISNB-UHFFFAOYSA-M sodium phenolate Chemical compound [Na+].[O-]C1=CC=CC=C1 NESLWCLHZZISNB-UHFFFAOYSA-M 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940107955 thymoglobulin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 108010057559 voclosporin Proteins 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Images
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110261928.1A CN102416217B (zh) | 2011-09-06 | 2011-09-06 | 药物治疗球囊扩张导管 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110261928.1A CN102416217B (zh) | 2011-09-06 | 2011-09-06 | 药物治疗球囊扩张导管 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102416217A CN102416217A (zh) | 2012-04-18 |
CN102416217B true CN102416217B (zh) | 2014-01-15 |
Family
ID=45941014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110261928.1A Active CN102416217B (zh) | 2011-09-06 | 2011-09-06 | 药物治疗球囊扩张导管 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102416217B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107242936A (zh) * | 2017-07-13 | 2017-10-13 | 柏为(武汉)医疗科技股份有限公司 | 一种治疗咽鼓管狭窄的载药装置 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104436421B (zh) * | 2014-11-28 | 2017-12-01 | 刘宗军 | 一种可灌注药物球囊 |
CN104922784A (zh) * | 2015-07-01 | 2015-09-23 | 乐普(北京)医疗器械股份有限公司 | 一种药物球囊导管 |
CN105771067A (zh) * | 2016-03-29 | 2016-07-20 | 中国人民解放军第二军医大学 | 低限制接触型高压球囊 |
US10940294B2 (en) * | 2016-04-25 | 2021-03-09 | Medtronic Vascular, Inc. | Balloon catheter including a drug delivery sheath |
CN106310495A (zh) * | 2016-08-22 | 2017-01-11 | 苗立夫 | 一种灌注扩张球囊系统 |
CN106178138A (zh) * | 2016-09-07 | 2016-12-07 | 上海申淇医疗科技有限公司 | 一种药物球囊 |
CN106512181A (zh) * | 2016-11-07 | 2017-03-22 | 恒壹(北京)医疗科技有限公司 | 一种带侧孔的球囊导管 |
CN106994204A (zh) * | 2017-03-28 | 2017-08-01 | 杭州唯强医疗科技有限公司 | 双球囊药物涂层球囊扩张导管 |
CN109938893A (zh) * | 2017-12-18 | 2019-06-28 | 上海微创医疗器械(集团)有限公司 | 球囊扩张导管及其药物球囊 |
CN111214749B (zh) * | 2019-12-18 | 2024-04-23 | 四川扬子江医疗器械有限公司 | 一种高压球囊导管及其制造方法 |
CN111408019A (zh) * | 2020-04-29 | 2020-07-14 | 童妍(上海)医疗器械有限公司 | 一种释药球囊导管及其释药方法 |
CN113262381A (zh) * | 2021-07-02 | 2021-08-17 | 深圳麦普奇医疗科技有限公司 | 球囊扩张导管 |
CN115054812B (zh) * | 2022-08-18 | 2022-11-11 | 广东博迈医疗科技股份有限公司 | 球囊导管装置 |
CN115054811A (zh) * | 2022-08-18 | 2022-09-16 | 山东瑞安泰医疗技术有限公司 | 一种能形成内源性血管支架的药物球囊导管装置 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101045175B (zh) * | 2006-03-29 | 2012-07-04 | 微创医疗器械(上海)有限公司 | 双层球囊导管 |
CN201058169Y (zh) * | 2007-05-24 | 2008-05-14 | 席刚明 | 一种同轴球囊溶栓导管 |
CN102125721A (zh) * | 2011-03-10 | 2011-07-20 | 微创医疗器械(上海)有限公司 | 一种新型介入医疗器械 |
-
2011
- 2011-09-06 CN CN201110261928.1A patent/CN102416217B/zh active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107242936A (zh) * | 2017-07-13 | 2017-10-13 | 柏为(武汉)医疗科技股份有限公司 | 一种治疗咽鼓管狭窄的载药装置 |
Also Published As
Publication number | Publication date |
---|---|
CN102416217A (zh) | 2012-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102416217B (zh) | 药物治疗球囊扩张导管 | |
US11752313B2 (en) | Balloon catheter including a drug delivery sheath | |
US6706013B1 (en) | Variable length drug delivery catheter | |
JP2017170186A (ja) | 封入薬物組成物およびその使用方法 | |
US20160331870A1 (en) | Drug Coated Balloon Catheter | |
EP2066388B1 (en) | Systems for local bioactive material delivery | |
WO2013097717A1 (zh) | 药物洗脱球囊导管 | |
CN102125721A (zh) | 一种新型介入医疗器械 | |
JP2010535074A (ja) | 改善された薬剤被覆医療製品,その製造及び使用方法 | |
CN106994204A (zh) | 双球囊药物涂层球囊扩张导管 | |
US20100076539A1 (en) | System for introducing an intraluminal endoprosthesis and method for manufacturing such a system | |
US20160067460A1 (en) | Balloon Catheter | |
CN102470196A (zh) | 药物输送用医疗器具 | |
CN104857616A (zh) | 一种可快速释放药物的载药球囊 | |
CN102526861A (zh) | 一种介入医疗器械 | |
CN107303406A (zh) | 一种球囊扩张导管 | |
CN104857615A (zh) | 一种新型双层药物球囊导管 | |
CN108784895A (zh) | 一种扩张支架系统 | |
CN116474245A (zh) | 一种球囊导管 | |
CN205903515U (zh) | 一种球囊扩张导管 | |
JPH04261668A (ja) | カテーテルチューブ | |
US20120283624A1 (en) | Drug Eluting Device and Method of Use Thereof | |
CN104254362A (zh) | 球囊导管 | |
CN219423543U (zh) | 一种球囊导管 | |
CN106178138A (zh) | 一种药物球囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 201203 Shanghai City Newton Road, Pudong New Area Zhangjiang hi tech Park No. 501 Applicant after: SHANGHAI MICROPORT MEDICAL (GROUP) Co.,Ltd. Address before: 201203 Shanghai City Newton Road, Pudong New Area Zhangjiang hi tech Park No. 501 Applicant before: MICROPORT MEDICAL (SHANGHAI) Co.,Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: WEICHUANG MEDICAL EQUIPMENT (SHANGHAI) CO., LTD. TO: SHANGHAI MICROPORT MEDICAL EQUIPMENT (GROUP) CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: MICROPORT ENDOVASCULAR (SHANGHAI) CO., LTD. Free format text: FORMER OWNER: SHANGHAI MICROPORT MEDICAL EQUIPMENT (GROUP) CO., LTD. Effective date: 20141021 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 PUDONG NEW AREA, SHANGHAI TO: 201318 PUDONG NEW AREA, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141021 Address after: 201318 Pudong New Area Kang Xin Road, Lane 3399, Lane 1, No. Patentee after: MICROPORT ENDOVASCULAR (SHANGHAI) Co.,Ltd. Address before: 201203 Shanghai City Newton Road, Pudong New Area Zhangjiang hi tech Park No. 501 Patentee before: SHANGHAI MICROPORT MEDICAL (GROUP) Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: No. 3399 Lane 1, Kangxin Highway, Pudong New District, Shanghai, 201318 Patentee after: SHANGHAI MICROPORT ENDOVASCULAR MEDTECH Co.,Ltd. Address before: No. 3399 Lane 1, Kangxin Highway, Pudong New District, Shanghai, 201318 Patentee before: MICROPORT ENDOVASCULAR (SHANGHAI) Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP03 | Change of name, title or address |
Address after: No. 3399 Lane 1, Kangxin Highway, Pudong New District, Shanghai, 201321 Patentee after: Shanghai minimally invasive heart pulse medical technology (Group) Co.,Ltd. Address before: No. 3399 Lane 1, Kangxin Highway, Pudong New District, Shanghai, 201318 Patentee before: SHANGHAI MICROPORT ENDOVASCULAR MEDTECH Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210208 Address after: Room 101, No.1, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, 201321 Patentee after: Shanghai Hongmai Medical Technology Co.,Ltd. Address before: No. 3399 Lane 1, Kangxin Highway, Pudong New District, Shanghai, 201321 Patentee before: Shanghai minimally invasive heart pulse medical technology (Group) Co.,Ltd. |
|
TR01 | Transfer of patent right |